NCT00273936已完成1 期
A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 10
研究概览
简要总结
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed chronic myelogenous leukemia, acute myeloid leukemia, acute lymphocytic leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, non-Hodgkin's lymphoma or Hodgkin's disease.
- •Patients must be refractory to, intolerant of, or decline to receive established therapy known to provide clinical benefit for their condition.
- •Age > 18 years
- •ECOG performance score of 0 or 1
- •Adequate renal function as evidenced by serum creatinine < 2.0 mg/dL
- •Adequate hepatic function as evidenced by:
- •Serum total bilirubin < 2.0 mg/dL (Patients with known Gilbert's syndrome may have total bilirubin values of up to 3 mg/dL.)
- •Alkaline phosphatase < 3X the upper limit of normal (ULN) for the reference lab (< 5X the ULN if considered related to underlying disease)
- •SGOT/SGPT < 3X the ULN for the reference lab (< 5X the ULN if considered related to underlying disease
- •Patients must be recovered from the clinically significant effects of any prior surgery, radiotherapy or other antineoplastic therapy.
- •Patients or their legal representatives must be able to read, understand and provide written informed consent to participate in the trial.
- •Women of childbearing potential as well as fertile men and their partners must agree to use an effective form of contraception during the study and for 90 days following the last dose of study medication (an effective form of contraception is an oral contraceptive or a double barrier method).
排除标准
- •Patients with an uncontrolled active infection
- •Prior treatment with an inosine-5-monophosphate dehydrogenase (IMPDH)-inhibitor
- •History of prior malignancy within the past 5 years except for curatively treated non-melanoma skin cancers, cervical intra-epithelial neoplasia, or localized prostate cancer with a current prostate specific antigen (PSA) of < 1.0 mg/dL Patients with other curatively treated malignancies who have no evidence of metastatic disease may be entered after discussion with the Medical Monitor.
- •Patients with known hypersensitivity to any of the components of AVN-944
- •Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 14 days of the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication). Clinically significant toxicities from this therapy must have resolved to < Grade
- •Grade 2 peripheral neuropathy
- •Patients who are pregnant or lactating
- •Any other intercurrent medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign the informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
- •History of solid organ transplant
- •Known HIV or hepatitis B or C (active, previously treated or both)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.Advanced Solid TumorAdult DiseaseLung CancerNCT04855929Anaveon AG55
终止
2 期
AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic CancerPancreatic CancerNCT00493441Vertex Pharmaceuticals Incorporated28
招募中
1 期
The Safety and Effectiveness of NV-A01 in Glioma PatientsAdvanced Glioblastoma PatientsNCT06193538First Affiliated Hospital of Wannan Medical College15
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic PainDiabetic NeuropathyNCT00576277Avigen36
已完成
1 期
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor MalignanciesNeoplasmsNCT00761696Infinity Pharmaceuticals, Inc.94